1. Home
  2. IMRN vs JDZG Comparison

IMRN vs JDZG Comparison

Compare IMRN & JDZG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • JDZG
  • Stock Information
  • Founded
  • IMRN 1994
  • JDZG 2020
  • Country
  • IMRN Australia
  • JDZG China
  • Employees
  • IMRN N/A
  • JDZG N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • JDZG Other Consumer Services
  • Sector
  • IMRN Health Care
  • JDZG Real Estate
  • Exchange
  • IMRN Nasdaq
  • JDZG Nasdaq
  • Market Cap
  • IMRN 15.0M
  • JDZG 15.2M
  • IPO Year
  • IMRN N/A
  • JDZG 2024
  • Fundamental
  • Price
  • IMRN $1.90
  • JDZG $0.67
  • Analyst Decision
  • IMRN Strong Buy
  • JDZG
  • Analyst Count
  • IMRN 1
  • JDZG 0
  • Target Price
  • IMRN $5.00
  • JDZG N/A
  • AVG Volume (30 Days)
  • IMRN 4.7K
  • JDZG 710.7K
  • Earning Date
  • IMRN 03-03-2025
  • JDZG 11-27-2024
  • Dividend Yield
  • IMRN N/A
  • JDZG N/A
  • EPS Growth
  • IMRN N/A
  • JDZG N/A
  • EPS
  • IMRN N/A
  • JDZG 0.06
  • Revenue
  • IMRN $3,271,194.00
  • JDZG $2,334,771.00
  • Revenue This Year
  • IMRN N/A
  • JDZG N/A
  • Revenue Next Year
  • IMRN N/A
  • JDZG N/A
  • P/E Ratio
  • IMRN N/A
  • JDZG $11.26
  • Revenue Growth
  • IMRN 171.67
  • JDZG 52.08
  • 52 Week Low
  • IMRN $1.65
  • JDZG $0.45
  • 52 Week High
  • IMRN $5.96
  • JDZG $15.08
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 43.76
  • JDZG N/A
  • Support Level
  • IMRN $1.89
  • JDZG N/A
  • Resistance Level
  • IMRN $2.05
  • JDZG N/A
  • Average True Range (ATR)
  • IMRN 0.08
  • JDZG 0.00
  • MACD
  • IMRN -0.02
  • JDZG 0.00
  • Stochastic Oscillator
  • IMRN 3.85
  • JDZG 0.00

About IMRN Immuron Limited

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About JDZG JIADE LIMITED Common stock

Jiade Ltd Ltd is engaged in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platforms and auxiliary solutions. The Group offers pre-enrollment guidance on school/selection and application development, training for entrance exams, and assistance in the application process. The Group also offers offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance in the People's Republic of China.

Share on Social Networks: